Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8 + Effector T-Cell Function for Synergistic Cancer Immunotherapy
ACS Central Science · 26.11.2025 · 11 (11) · 2087-2107
DOI: 10.1021/acscentsci.5c00812 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Central Science, online erschienen am 16.09.2025. Verfasst von Keyi Ao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong …. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Foundation of Shenzhen City, National Natural Science Foundation of China, Shenzhen Hospital, Southern Medical University.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Tumor resistance to immune checkpoint blockade (ICB) therapy is frequently driven by adaptive metabolic reprogramming in the hypoxic tumor microenvironment (TME). The key N4-acetylcytidine (ac4C) RNA modification mediator N-acetyltransferase 10 (NAT10) emerges as a promising therapeutic target, despite the lack of potent targeting agents. Here, we engineered NP1192, a PROTAC degrader targeting NAT10. NP1192 achieved nearly 70% NAT10 degradation and a 26.8% lower IC 50 than canonical NAT10 inhibitor Remodelin in cervical cancer cells, outperforming Remodelin in antitumor effect in vivo, in vitro, and across three tumor organoids. It abrogated ac4C modifications on HIF1A mRNA and translation, reducing hypoxic lactate production and depleted ATP, and suppressed HIF-1α-mediated PD-L1 upregulation. In xenograft models, NP1192 combined with anti-PD-L1 inhibited subcutaneous xenograft growth and reduced tumor-core lactate gradients by > 80%. Furthermore, scRNA-seq and in vitro coculture experiments identified expansion of IFN-γ + effector CD8 + T cells (T eff ) and decline in exhausted CD8 + T cells (T ex ). NP1192 in combination with anti-PD-L1 enhanced proliferation and effector function of CD8 + T eff cells, thereby reversing resistance to anti-PD-L1 blockade therapy and synergizing with immunotherapy. These findings establish PROTAC-mediated NAT10 degradation as a dual metabolic-immune strategy to enhance checkpoint blockade efficacy.
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
- Shenzhen School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong 510515, P. R. China.
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515,…
- Department of Ultrasound, South China Hospital, Medical School, Shenzhen University, Shenzhen, Guangdong 518116, P. R. China.
- Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, P. R. China.
- Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong…
ORCID-Profile: Jianjun Chen, Xia Guo
Förderung
- Science and Technology Foundation of Shenzhen City
- National Natural Science Foundation of China
- Shenzhen Hospital, Southern Medical University
- Shenzhen University
- Shenzhen Key Laboratory of Viral Oncology
- Shenzhen Medical Research fund
Zitieren
APA
Ao, K., Sun, Z., Hao, Y., Qin, J., Xu, C., Wen, X., Yang, Z., Li, L., Gan, S., Chen, X., Li, X., Zhang, J., Chen, J., & Guo, X. (2025). Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8 + Effector T-Cell Function for Synergistic Cancer Immunotherapy. ACS Central Science, 11(11), 2087-2107. https://doi.org/10.1021/acscentsci.5c00812
Vancouver
Ao K, Sun Z, Hao Y, Qin J, Xu C, Wen X, et al. Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8 + Effector T-Cell Function for Synergistic Cancer Immunotherapy. ACS Central Science. 2025;11(11):2087-2107. doi:10.1021/acscentsci.5c00812
BibTeX
@article{Ao2025,
author = {Ao, Keyi and Sun, Zhiqiang and Hao, Yi and Qin, Jiaqi and Xu, Chenglong and Wen, Xiuli and Yang, Zichao and Li, Li and Gan, Shaoyan and Chen, Xiaona and Li, Xin and Zhang, Jian and Chen, Jianjun and Guo, Xia},
title = {Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8 + Effector T-Cell Function for Synergistic Cancer Immunotherapy},
journal = {ACS Central Science},
year = {2025},
volume = {11},
number = {11},
pages = {2087--2107},
doi = {10.1021/acscentsci.5c00812}
}
EUVIMED